3 Healthcare Stock Stories For Monday Investment Wellness

Biogen IDEC (NASDAQ: BIIB): Closing price $222.74

On Monday Biogen said that the FDA has accepted its Biologics License Application for the marketing approval of Eloctate (recombinant factor VIII Fc fusion protein) for the treatment of hemophilia A. Eloctate is the first hemophilia A product candidate in a new class of long-lasting clotting factor therapies being created with the goal of providing long-lasting protection and lowering the burden of treatment for patients suffering with this chronic condition.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BIIB

Pluristem Therapeutics (NASDAQ:PSTI): Closing price $3.04

Pluristem announced Monday that its placental expanded cells tested in preclinical animal models of preeclampsia effectively improved several parameters of the disease. The evaluation was run in collaboration with Associate Professor of Internal Medicine at the Cardiovascular Research Institute of the Texas A&M College of Medicine Brett Mitchel PhD. Mitchel will present details of the study on May 30 at the Society for Gynecological Investigation Summit in Jerusalem.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

PSTI

Theragenics Corporation (NYSE: TGX): Closing price $2.03

The medical device firm on Monday announced that its board has received a proposal from Juniper Investment Company to purchase all of its outstanding common stock at between $2.25 and $2.30 per share in cash. Theragenics has entered into an agreement dated May 12 to deal and negotiate exclusively with Juniper through June 11 in connection with a merger transaction. The $2.25 to $2.30 per share range reflects a negotiated increase from a $2.05 to $2.10 per-share range which Juniper initially proposed in its letter dated May 10 to Theragenics.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

TGX

Don’t Miss: Is This Obamacare Provision a Threat to Food Companies?